Squarepoint
PACB icon

Squarepoint’s Pacific Biosciences PACB Stock Holding History

Squarepoint’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,900
Closed -$25.5K – 4716
2025
Q3 		$25.5K Hold
19,900
– – ﹤0.01% 4276
2025
Q2 		$24.7K Sell
19,900
-400
-2% -$462 ﹤0.01% 4375
2025
Q1 		$24K Sell
20,300
-12,700
-38% -$19.5K ﹤0.01% 4425
2024
Q4 		$60.4K Buy
+33,000
New +$64.4K ﹤0.01% 4808

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's PACB Position: Q2 2026 in Review

Squarepoint opened a new position in Pacific Biosciences (PACB) in Q2 2026: 41,776 shares worth $70.2K. The stake represents ﹤0.01% of the portfolio and ranks #4242 among its holdings. This is a return to the name: Squarepoint previously reported a position in PACB as recently as Q4 2025.

Squarepoint first reported a position in PACB in Q4 2014 and has held it in 29 quarters since. The position peaked at $9.62M in Q3 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Squarepoint held 41,776 shares of Pacific Biosciences worth $70.2K as of Q2 2026.
  • Pacific Biosciences was a new Squarepoint position in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4242 holding.
  • Squarepoint first reported a position in Pacific Biosciences in Q4 2014 and has held it in 29 quarters since.
  • Squarepoint's Pacific Biosciences position peaked at $9.62M in Q3 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.